MoleculeMind Secures Hundreds of Millions in Series A Funding to Accelerate AI-Driven Bioeconomic Infrastructure

(Synthetic Biology Network) InIntelligent Upgrade of BioeconomyIn the wave of,Industry-leadingAIProtein design platform company MoleculeMind announcesInRecentlyCompletedSeries AFinancing. The amount of this round of financingAchieveNumberHundred MillionCNY，ByXieNuo Investment and Shenzhen Capital Group UnitedLead investment,SenseTime Guoxiang Capital and Jiuyi Investment followed suit. As a benchmark in the industryTheMoleculeMind, an AI biomacromolecule design platform company, will further accelerate the construction of AI biological infrastructure with this round of financing.

MoleculeMind founder and internationally renowned computational biologist Jinbo Xu stated that this round of financing will be used to further expand the top interdisciplinary talent team and deeply refine.AIProtein Foundation Large Model,AIProtein Optimization Design PlatformMoleculeOSand other bioeconomy common technology platforms, acceleratingAIThe industrial implementation and commercialization process of protein technology."We use AIDesign super proteins that surpass natural evolution, and throughAIProtein Infrastructure Construction: Transforming the Scientific Challenge of Protein Design"‘Programmable’ and ‘Predictable’ Engineering Problems."

In addition, MoleculeMind will explore systematic optimization design for the entire R&D and production process in the bioeconomy field, ranging from protein component design to metabolic pathway design and process optimization.

As of now, MoleculeMind has cumulatively completedThree rounds of financing, with previous investors including Cathay Biotech, a leading company in synthetic biology, Sequoia China, Baidu BV, Legend Capital, etc.

Continuously from0 to 1 Innovation: Developing World-Leading AI Protein Technology to Tackle Industry Challenges

Proteins are the core material foundation of the bioeconomy. The fields of biopharmaceuticals and biomanufacturing have a huge demand for functional proteins, but discovering proteins with ideal functions from nature is extremely challenging. Traditional methods mostly rely on wet-lab screening, which is time-consuming, costly, and has a low success rate, severely limiting the rapid development of biopharmaceuticals and biomanufacturing.

MoleculeMind is based on the globally leadingAIProtein technology, integrating scientific computational methods such as molecular dynamics and quantum chemistry, achieves precise optimization and design of proteins with small or even zero samples, eliminating the need for high-throughput screening. Only a few wet lab validations are required to accurately obtain the desired protein.Greatly EnhanceEfficiency and success rate of performance optimization and de novo design for various types of proteins, including antibodies, enzymes, small proteins, vaccines, etc.。

AsAIOne of the few in the protein field with the ability fromCompanies with 0 to 1 innovation capabilities, such as MoleculeMind, possess globally leading technical expertise and application experience in highly valuable yet extremely challenging fields like protein dynamic binding design. Protein dynamic binding design can address application challenges such as enzyme activity optimization, offering broad industrial applications. However, due to its high complexity, there are currently no publicly available mature methods worldwide. Mainstream algorithms in the industry, like AlphaFold, are limited to predicting static protein structures and are unable to tackle this issue.MoleculeMind's self-developed protein dynamic binding design algorithm effectively avoids the widespread false positive issues present in current mainstream algorithms and large models., with both precision and success rate at leading levels.

As of now, MoleculeMind has independently developed more than ten performance-leadingAI protein prediction, optimization, and design algorithms, such as NewOrigin (Darwin), the world's first industrial-grade AI protein generation large model integrating sequence, structure, function, and evolution.Precision BeyondAlphaFold Complex 3StructurePrediction Algorithm, the world's firstAn Algorithm for Simultaneous Protein Side-Chain Prediction and Sequence Designetc.,The relevant achievements have been published multiple times inSSCIENCE Magazine, Proceedings of the National Academy of Sciences USAand other core journals, winning honors such as the first International Basic Science Conference Frontier Breakthrough Award. Organized by the Nobel Prize FoundationAt the "Latest Advances in the Human 3D Proteome" seminar, Xu Jinbo was the only guest from mainland China.

Based on revolutionaryAIProtein design technology: MoleculeMind has made breakthroughs in challenging industrial issues such as enzyme activity optimization design and protein performance optimization under extreme conditions. Based on an understanding of the design of biological components like proteins, it systematically optimizes key aspects of biological reaction processes, including metabolic pathways, strain construction, fermentation techniques, and scale-up processes.

In a joint industrial project with leading pharmaceutical companies to optimize their core enzyme raw materials, MoleculeMind utilizedAITechnology designs an enzyme with extremely complex functions and a very large molecular weight. Since the enzyme reaches the limit of the expression system, it is extremely difficult to modify using wet-lab methods, and there have been no similar successful cases reported globally before. MoleculeMind is based onAIDe novo design of a new enzyme that does not exist in nature, inRetain Functional Activitywhile reducing the molecular weight60%, breaking through the multi-objective optimization challenges that traditional experimental methods could not achieve.

Behind these leading technologies is a teamHasAI Biology Crossover Background and Deep IndustryExperienceTheA Team of Multi-skilled Talents. Professor Jinbo Xu, founder of MoleculeMind, is highly regarded in the industry."The Founder of AI Protein Folding" praised, once in 2016First used globally in yearAIThe method breaks through the century-old problem of protein structure prediction, and its pioneering technical route has beenDeepMind used forAThe development of AlphaFold has unveiled the curtain on AI protein structure prediction and AI protein design.022In the year, Xu Jinbo returned to China and founded MoleculeMind, attracting a group of professionals from...MIT, Yale, Caltech, Tsinghua, Peking University and other top universitiesAndWuXi, Novozymes,Meta, Amazon, Baidu, Alibaba, ByteDance,Discovery Studioetc.HeadThe company's top talents. In thisSupportGlobally Scarce Top-TierTeamProceed, MoleculeMind continuesBreakthrough TechnologyBoundary, forThe biotechnology sector brings a transformative engine.

Building Bioeconomic Infrastructure, Commercialization Accelerates

WithAI Protein Technology Innovation and Industrial Application: MoleculeMind's Commercialization Progresses Steadily. In 2023, Cathay Biotech, a leading company in synthetic biology, made a strategic investment in MoleculeMind and integrated AI protein technology into its R&D system. Recently, Liu Xiucái, Chairman of Cathay Biotech, announced significant progress in their collaboration, stating that "in the optimization of key proteins, an important enzyme protein structure designed by artificial intelligence has increased the yield of the strain fivefold compared to the wild strain."

In the broader biomanufacturing market,MoleculeMind has reached deep cooperation with leading companies in the fields of medicine, materials, chemical industry, food, agriculture, etc., usingAI Protein Technology Breaks Through the Limitations of Traditional Biological Methods, Designs Superior Enzymes with Enhanced Performance, and Empowers the Next Generation.Design and Process Optimization of Xie (MoleculeMind)And other biomanufacturing processes.

In the field of innovative drugs, MoleculeMind is based onAIProtein design technology self-developed cytokine pipeline,While maintaining the ability to suppress tumor activity, it has been attenuated (reducing peripheral activity) hundreds of times.The dose tolerated by monkeys reached dozens of times that of similar pipelines. In the protein vaccine design project, MoleculeMind simultaneouslyMulti-objective optimization of protein vaccine stability, expression levels, etc.,ThroughAnimal ExperimentVerification, Vaccine ProductionTheThe titer of neutralizing antibodies is several times higher than that of publicly patented and large pharmaceutical companies' protein vaccines, breaking through related vaccine stability patents.

More noteworthy is that, among these industrial projects,AIDesigning proteins is as simple as3-4In just a few days, with only a small amount of wet lab validation required, ideal candidate molecules can be obtained. The previous time-consuming high-throughput wet lab screening model is shifting towards..."Precision Design + Minimal Validation" Transformation: The Underlying Model of the Bioeconomy is Upgrading Driven by New Technologies.

To AccelerateAIThe落地application of protein design technology, MoleculeMind has independently developed the world's first industry-level integration of sequence, structure, function, and evolution.AI Protein Generation Large Model NewOrigin (Darwin),PossibleTo meet industrial application needs within hours, or even minutes"Customizing" proteins with specific functions boasts high success rates, strong versatility, and low usage barriers. Meanwhile, MoleculeMind has integrated the NewOrigin large model into a one-stop AIProtein Prediction, Optimization, and Design PlatformIn MoleculeOS, users from different backgrounds and with different needs in the bioeconomy field are provided with...API, software, solutions, technical services and other forms of protein design tools and services, by building an infrastructure platform to reduceAIThe application threshold of protein technology.

Currently, the bioeconomy has been listed as a strategic field by dozens of countries around the world, becoming a new focal point of international competition. The global market continues to boom, with the core markets of biopharmaceuticals and biomanufacturing each reaching hundreds of billions of dollars. The compound annual growth rate of the biopharmaceutical market exceeds10%, the biomanufacturing market is growing at an even faster rate of over26%The compound annual growth rate is expanding rapidly. In this global race,AIProtein technology is becoming a revolutionary force in reshaping the bioeconomy landscape.

Wei Xiaolin, founding partner of Chenow Investment and chairman of the Investment Committee, said,"AI-based protein structure prediction represented by AlphaFold-2 is one of the most significant and groundbreaking scientific advancements of this century. Professor Jinbo Xu, the founder of MoleculeMind, has made pioneering contributions in this field. The leap from protein structure prediction to de novo protein design is even greater, and MoleculeMind has built an outstanding technical platform for this purpose, achieving impressive progress. At the same time, the MoleculeMind team is highly efficient, fast-learning, and precise in commercialization, with rapid commercial implementation across multiple fields, from supporting synthetic biology to large-molecule drug discovery. This commercial work, in turn, accelerates the iteration and enrichment of MoleculeMind's technical platform. XieNuo Investment firmly believes in the power of science and mission, and the future where AI benefits humanity and creates value is within reach. We are honored to be partnering with such an excellent team as MoleculeMind to jointly create the future."

Zhou Yi, General Manager of Shenzhen Capital Group's Health Industry Investment Department, stated:"Intelligent infrastructure is an efficient engine to accelerate the development of the synthetic biology industry. The MoleculeMind teamAIDecades of R&D and application experience in the field of proteins, as well asAILarge protein models and industrial application platforms will solidify the underlying technical foundation for the development of the synthetic biology industry. Looking forward to the next phase.AIThe Integration and Scalable Explosion of Protein New Technologies with the Biomanufacturing Industry.”

Shang Tang Guoxiang Capital Management Partner Hu Yutong said:"MoleculeMind's practical achievements in AI protein optimization design demonstrate the immense potential of generative AI in this field, which can help accelerate transformations in synthetic biology and the pharmaceutical industry. Leveraging SenseTime’s comprehensive advantages in AI infrastructure and large models, both parties will jointly explore broader innovative spaces for AI technology in the biological domain."

A partner of Jiuyi Capital stated:"Jiuyi focuses on high-tech fields. MoleculeMind is not only AIThe leader in protein design technology, alsoAIThe integration of technology and biomanufacturing has set a benchmark. The current transformation in biomanufacturing is still in its early stages, and we are excited to collaborate with a world-class team to accelerate this process.AIThe Era of Biomanufacturing Has Arrived.”

Conference Recommendation:Grand Gathering of Experts! First Round of Agenda for the Synthetic Biology and Biomanufacturing Applications Conference on September 21-22 Announced (With Guest List)